Genesystem Co. Ltd. (363250) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of Genesystem Co. Ltd. stock KRW 2,749, price KRW 4,100, that is 32.9% below the price, quality 30 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Genesystem Co. Ltd.
363250 · KQExpensive (fair value 33% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range 2,995 KRW – 31,900 KRW · fair‑value band 2,062 KRW – 3,437 KRW · the 4,100 KRW price screens above the 2,749 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Genesystem Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Genesystem Co., Ltd., a biotech engineering company, specializes in molecular testing solutions to target on-site testing needs. The company offers PCR systems, multiplex biochips, and PCR reagents.
Show moreShow less
It also provides human pathogen assays, including novel coronavirus (SARS-CoV-2) detection kits, SARS-CoV-2/Flu/RSV simultaneous detection kits, and mycobacterium tuberculosis detection kits; veterinary diagnostics; food safety assays comprising foodborne pathogen detection kits, HALAL food testing kits, and meat species identification kits; and nucleic acid extraction assays, such as extraction kits, extraction buffers, lysis buffers, and gDNA extraction kits.
The company was incorporated in 2010 and is based in Daejeon, South Korea.
Stock analysis
Genesystem Co. Ltd. (363250) currently trades at 4,100 KRW, while our estimate is 2,749 KRW, 33% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: 2,062 KRW (bear) to 3,437 KRW (bull), the price of 4,100 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Genesystem Co. Ltd. reported revenue of 381M KRW in FY2025 versus 13.2B KRW in FY2021, a compound −58.8%/yr. Reported net income was −12.0B KRW in FY2025.
Key figures
Market cap 34.0B KRW (≈ $25.4M) Micro · P/S ratio 35.6 · EPS (TTM) −1,241 KRW · Return on equity −86.8% · Return on assets (EBIT) −27.4% (5-year average) · Operating margin −222% · Revenue (TTM) 1.0B KRW · Revenue growth (YoY) +523%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 3 out of 100 (low confidence).
What moves the price
The share trades about 41% below its 52-week high and 37% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −33%, 363250 screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare Genesystem Co. Ltd. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 151 stocks
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Return on equity by industry
- Quality Score by industry
- Stock screener with 62 metrics
- Undervalued stocks: South Korean Stocks
- Valuation of the Korea market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Illumina, Inc ILMN | $198.00 | $227.71 | +15% | vs 363250 |
| WuXi AppTec Co 603259 | ¥146.07 | ¥164.66 | +13% | vs 363250 |
| IQVIA Holdings IQV | $264.73 | $291.63 | +10% | vs 363250 |
| Thermo Fisher Scientific Inc TMO | $691.33 | $686.04 | −1% | vs 363250 |
| Danaher Corporation DHR | $229.91 | $209.18 | −9% | vs 363250 |
| IDEXX Laboratories, Inc IDXX | $700.65 | $496.48 | −29% | vs 363250 |
| Lonza Group LONN | CHF 663.00 | CHF 259.80 | −61% | vs 363250 |
| Mettler-Toledo International Inc MTD | $1,727 | $655.06 | −62% | vs 363250 |
| Agilent Technologies, Inc A | $172.92 | $64.20 | −63% | vs 363250 |
| Waters Corporation WAT | $453.42 | $91.26 | −80% | vs 363250 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Genesystem Co. Ltd. (363250) overvalued or undervalued?
What is the fair value of 363250?
What is the quality score of 363250?
What is the price target for Genesystem Co. Ltd. (363250)?
What is the Genesystem Co. Ltd. stock forecast for 2026?
What is the revenue of Genesystem Co. Ltd. (363250)?
What is the intrinsic value of Genesystem Co. Ltd. (363250)?
Is Genesystem Co. Ltd. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 363250?
How much is Genesystem Co. Ltd. worth?
What do the bullish and bearish scenarios say about 363250?
How solid is the balance sheet of Genesystem Co. Ltd. (363250)?
How far is 363250 from its 52-week high?
Which stocks are comparable to Genesystem Co. Ltd.?
Is Genesystem Co. Ltd. stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Genesystem Co. Ltd. (363250)?
What should I pay attention to with Genesystem Co. Ltd. right now?
Key figures of Genesystem Co. Ltd.
How large is the market capitalisation of Genesystem Co. Ltd. (363250)?
What is the P/S ratio of Genesystem Co. Ltd. (363250)?
What are the earnings per share of Genesystem Co. Ltd. (363250)?
What is the return on equity of Genesystem Co. Ltd. (363250)?
What is the EBIT return on assets of Genesystem Co. Ltd. (363250)?
What is the operating margin of Genesystem Co. Ltd. (363250)?
How fast is revenue growing at Genesystem Co. Ltd. (363250)?
How much free cash flow does Genesystem Co. Ltd. (363250) generate?
How much net debt does Genesystem Co. Ltd. (363250) carry?
Watch Genesystem Co. Ltd. in the live analysis
One click puts Genesystem Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.